Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)

NAActive, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Obsessive-Compulsive Disorder
Interventions
DEVICE

Activa PC+S DBS implant for OCD

"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"

OTHER

One Month Blinded Discontinuation Period

"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."

Trial Locations (3)

15260

University of Pittsburgh, Pittsburgh

77030

Baylor College of Medicine, Houston

02912

Brown University, Providence

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

Brown University

OTHER

collaborator

Carnegie Mellon University

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Medtronic

INDUSTRY

lead

Baylor College of Medicine

OTHER